Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

Article Abstract:

The efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen was compared with the efficacy and safety of the optimized background regimen alone. It was concluded that the addition of enfuvirtide to an optimized background regimen provided significant viral suppression and immunologic benefit over a 24-week period in HIV-1-infected patients who had previously received multiple antiretroviral drugs.

Australia

---

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Article Abstract:

A randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor was conducted through the T-20 vs. Optimized Regimen Only Study 1 (TORO 1). It was concluded that the addition of enfuvirtide to an optimized antiretroviral regimen provided significant antiretroviral and immunologic benefit through 24 weeks in patients who had previously received multiple antiretroviral drugs and had multidrug-resistant HIV-1 infection.

---

Similar abstracts:

• Abstracts: Efficacy of thermal balloon ablation in patients with abnormal uterine bleeding. Use of health services associated with increased menstrual loss in the United States
• Abstracts: Inhaled nitric oxide in premature infants with the respiratory distress syndrome. Nitric oxide for preemies -- not so fast
• Abstracts: Macrosomic births in the United States: determinants, outcomes, and proposed grades of risk. Effect of advanced maternal age on early mortality among quadruplets and quintuplets
• Abstracts: HMOs liable for actions of their network doctors. Punitive damages diverted to court-created cancer fund
• Abstracts: More California physicians rejecting new HMO patients. Calif. doctors protected on medical pot, but issue far from over

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.